^
Association details:
| Biomarker: | IFNG overexpression |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) + Anniko (penpulimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Published date:
11/27/2023
Excerpt:
Patients received penpulimab (200mg, IV, D1) and Anlotinib (12mg, P.O, QD, D1-14), in addition to nab-paclitaxel (125mg/m2, I.V, D1,8) and gemcitabine (1.0g/m2, I.V, D1,8), administered over a 21-day treatment cycle….In prespecified exploratory transcriptomic biomarkers analysis, significantly higher expression of IFN-γ, T cell recruiting and Th17 recruiting scores were detected in CR/PR patients compared with SD/PD patients.
Secondary therapy:
gemcitabine + albumin-bound paclitaxel
Trial ID:
